Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Identifieur interne : 002803 ( Ncbi/Curation ); précédent : 002802; suivant : 002804Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Auteurs : Bingwen Liu [République populaire de Chine] ; Min Li [République populaire de Chine] ; Zhiguang Zhou [République populaire de Chine] ; Xuan Guan [États-Unis] ; Yufei Xiang [République populaire de Chine]Source :
- Journal of autoimmunity [ 1095-9157 ] ; 2020.
Abstract
The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.
DOI: 10.1016/j.jaut.2020.102452
PubMed: 32291137
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000030
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000030
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000273
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002803
Links to Exploration step
pubmed:32291137Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?</title><author><name sortKey="Liu, Bingwen" sort="Liu, Bingwen" uniqKey="Liu B" first="Bingwen" last="Liu">Bingwen Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Min" sort="Li, Min" uniqKey="Li M" first="Min" last="Li">Min Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha</wicri:regionArea><wicri:noRegion>Changsha</wicri:noRegion></affiliation></author><author><name sortKey="Zhou, Zhiguang" sort="Zhou, Zhiguang" uniqKey="Zhou Z" first="Zhiguang" last="Zhou">Zhiguang Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Guan, Xuan" sort="Guan, Xuan" uniqKey="Guan X" first="Xuan" last="Guan">Xuan Guan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, AdventHealth Orlando, Orlando, USA. Electronic address: xuan.guan.md@adventhealth.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, AdventHealth Orlando, Orlando</wicri:regionArea><wicri:noRegion>Orlando</wicri:noRegion></affiliation></author><author><name sortKey="Xiang, Yufei" sort="Xiang, Yufei" uniqKey="Xiang Y" first="Yufei" last="Xiang">Yufei Xiang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China. Electronic address: yufei.xiang@csu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32291137</idno><idno type="pmid">32291137</idno><idno type="doi">10.1016/j.jaut.2020.102452</idno><idno type="wicri:Area/PubMed/Corpus">000030</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000030</idno><idno type="wicri:Area/PubMed/Curation">000030</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000030</idno><idno type="wicri:Area/PubMed/Checkpoint">000273</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000273</idno><idno type="wicri:Area/Ncbi/Merge">002803</idno><idno type="wicri:Area/Ncbi/Curation">002803</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?</title><author><name sortKey="Liu, Bingwen" sort="Liu, Bingwen" uniqKey="Liu B" first="Bingwen" last="Liu">Bingwen Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Li, Min" sort="Li, Min" uniqKey="Li M" first="Min" last="Li">Min Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha</wicri:regionArea><wicri:noRegion>Changsha</wicri:noRegion></affiliation></author><author><name sortKey="Zhou, Zhiguang" sort="Zhou, Zhiguang" uniqKey="Zhou Z" first="Zhiguang" last="Zhou">Zhiguang Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Guan, Xuan" sort="Guan, Xuan" uniqKey="Guan X" first="Xuan" last="Guan">Xuan Guan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, AdventHealth Orlando, Orlando, USA. Electronic address: xuan.guan.md@adventhealth.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, AdventHealth Orlando, Orlando</wicri:regionArea><wicri:noRegion>Orlando</wicri:noRegion></affiliation></author><author><name sortKey="Xiang, Yufei" sort="Xiang, Yufei" uniqKey="Xiang Y" first="Yufei" last="Xiang">Yufei Xiang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan, China. Electronic address: yufei.xiang@csu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of autoimmunity</title><idno type="eISSN">1095-9157</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002803 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002803 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:32291137
|texte= Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:32291137" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |